So honored to receive the Outstanding Clinical #Mentor award from our graduating heme-onc fellows @UMNews
It is an absolute honor to lead this program!
#Mentorship#MedEd#Leadership
We built OncoSphere AI: an agentic AI system designed for real multidisciplinary oncology workflows.
Not a chatbot. Not a summarizer. An autonomous agent that reasons across guidelines, trial data, imaging, and pathology to support clinical decision-making the way a tumor board actually works.
Presenting at #ASCO26 @ASCO: https://t.co/4kz8W5xzDw
The oncology AI tools that will matter aren't the ones that answer questions. They're the ones that run workflows navigation, trial matching, treatment sequencing, toxicity guidance, end to end.
That's what agentic AI means. That's what we're building!
@BLSintServices Everytime there is an appointment opening and we are trying to book it the website keeps crashing or gives error
This is a disapointing experience @EmbEspIndia
@BLSintServices
Hi,
I am unable to find any open slots for a spain visa appointment for my father in delhi or nearby.
Would really appreciate your help with this
Amphicrine prostate cancer may be a transitional state between prostate adenoCa and small cell/NEPC. Upregulation of FOXA1 and OTX2 may play a role. Congrats to Megan Ludwig for this deep multi-omic analysis. @UMNCancer@umn_dom@DrJustinDrake@aliarafaa https://t.co/Ix58SW3moU
Largest ctDNA analysis of activating AR-LBD mutations using >15,000 samples from mCRPC pts. These data inform therapeutics such as PROTACs (ARV- drugs) and CYP11 inhibitors (ODM-208) which have preferential activity in AR-LBD-mutated PCa. @GuardantHealth https://t.co/Dvu7Zbq6tf